In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.

doi:10.1016/S0960-894X(98)00380-1

Paper

In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.

Published Aug 18, 1998 · Z. Q. Xu, R. Buckheit, T. L. Stup

Bioorganic & medicinal chemistry letters

Q2 SJR score

34

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

12-oxocalanolide A, a novel NNRTI, shows in vitro anti-HIV and simian immunodeficiency virus activity, making it the first reported calanolide analogue capable of inhibiting SIV.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.

References

Citations